Avaí Bio has initiated manufacturing a Master Cell Bank of genetically modified cells that overexpress α-Klotho protein, a key step toward scalable production of regenerative medicine products. Their unique Cell-in-a-Box® encapsulation technology protects therapeutic cells, enabling off-the-shelf delivery without immune rejection, addressing a major manufacturing challenge in the $578 billion regenerative medicine market. This breakthrough supports Avaí Bio's programs targeting aging-related diseases and diabetes, positioning the company to capitalize on the growing demand for reliable, large-scale cell therapies. The market potential spans Alzheimer's, cardiovascular, and kidney diseases, with significant unmet needs for effective treatments.
Shirofune has introduced Walmart Connect, an integration that allows advertisers and agencies to manage Walmart retail media campaigns alongside other digital channels within a single platform. This automation reduces manual bid adjustments and repor...
Purecore Metals Inc. has signed a non-binding letter of intent with Skyharbour Resources to acquire an option to earn up to 100% interest in the Yurchison uranium property in Saskatchewan's Athabasca Basin. The property covers over 35,000 hectares an...
Point completed a $508.6 million rated asset-backed securitization of its Home Equity Investment (HEI) assets, marking the largest transaction ever in the HEI asset class. The deal attracted over 30 institutional investors and priced at significantly...
The global reactive hot melt adhesives market is projected to grow from $2.02 billion in 2025 to $4.29 billion by 2035, at a CAGR of 7.72%. Growth is driven by regulations limiting solvent-based adhesives, increased use of polyurethane adhesives in a...
Industrial Development Funding (IDF) and Oaktree have committed $1.7 billion to support Bloom Energy's fuel cell technology for building AI cloud infrastructure for Nebius. This project will provide dedicated behind-the-meter power to meet the high c...
